SAGE
vs
S&P 500
SAGE
S&P 500
Over the past 12 months, SAGE has significantly outperformed S&P 500, delivering a return of +74% compared to the S&P 500's +16% growth.
Stocks Performance
SAGE vs S&P 500
Performance Gap
SAGE vs S&P 500
Performance By Year
SAGE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
SAGE Therapeutics Inc
Glance View
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.